"investor" has been shown over and over again to deliberately misstate the facts. There is no basis for believing anything that "investor", "doc", and several others write.
It depends on how you understand "normal protocol" -- is it what other companies use as a statistical measurement for this indication (or in the ordinary clinical trial), or is it what biostatisticians would support using in the event of a non-parametric distribution curve? Do we have such a non-parametric curve here?
News 
Market Data 
Discover 
